An important endpoint in treating chronic kidney disease, a prevalent disease that can lead to kidney failure and cardiovascular disease, is reducing proteinuria. Proteinuria is an independent risk factor for disease progression and the development of cardiovascular disease and is a key factor that can be used to guide therapy designed to maximize kidney protection. Proteinuria is targeted by using pharmacologic agents that suppress the renin-angiotensin-aldosterone system (RAAS), a regulator of intravascular volume and blood pressure; this has been shown to decrease proteinuria, slow disease progression, and improve coronary disease outcome, independent of effects on blood pressure. The efficacy of RAAS blockers, including angiotensin receptor blockers and angiotensin-converting enzyme inhibitors, may be limited by currently recommended doses, which are based on treatment of hypertension. Data are now emerging from clinical trials demonstrating that use of ‘supratherapeutic doses’ (doses greater than those approved for lowering blood pressure), compared with standard doses, has favorable safety, tolerability, and efficacy in reducing proteinuria in both diabetic and nondiabetic patients with chronic kidney disease. Supratherapeutic dosing may be a valuable approach for optimizing RAAS blockade and providing renoprotection.

Keywords:
Chronic kidney disease, Proteinuria, Supratherapeutic doses, Angiotensin receptor blockers, Renin-angiotensin-aldosterone system
1.
National Kidney Foundation-Kidney Disease Outcomes Quality Initiative: K-DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(suppl 2):S12–S154.
2.
Saydah S, Eberhardt M, Rios-Burrows N, Williams D, Geiss L, Dorsey R, Centers for Disease Control and Prevention: Prevalence of chronic kidney disease and associated risk factors – United States, 1999–2004. MMWR Morb Mortal Wkly Rep 2007;56:161–165.
3.
US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006. http://www.usrds.org/adr.htm.
4.
Hsu C, Vittinghoff E, Lin F, Shilpak MG: Incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95–101.
5.
Mainous AG III, Baker R, Koopman RJ, Saxena S, Diaz VA, Everett CJ, Majeed A: Impact of the population at risk of diabetes and projections of diabetes burden in the United States: an epidemic on the way. Diabetologia 2007;50:934–940.
6.
Praga M: Therapeutic measures in proteinuric nephropathy. Kidney Int 2005;68:S137–S141.
7.
Kelley K, Aricak OT, Light RP, Agarwal R: Proteinuria is a determinant of quality of life in diabetic nephropathy: modeling lagged effects with path analysis. Am J Nephrol 2007;27:488–494.
8.
Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281–287.
9.
De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309–2320.
10.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS, AIPRD Study Group: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131–1140.
11.
Agarwal R: Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications. Am J Nephrol 2007;27:92–100.
12.
Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985;313:1617–1620.
13.
Agarwal R, Andersen MJ: Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 2005;46:514–520.
14.
Kakuta H, et al: Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41–46.
15.
Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282–2289.
16.
Agarwal R: Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003;284:F863–F869.
17.
GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863.
18.
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998;53:1209–1216.
19.
Ruggenenti P, Perna A, Remuzzi G; on behalf of the Investigators of the GISEN Group: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003;63:2254–2261.
20.
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.
21.
Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 2002;106:1777–1782.
22.
Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007;115:69–84.
23.
Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N: Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004;15:1475–1487.
24.
Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators: Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52–61.
25.
Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med2000;342:145–153.
26.
ONTARGET: ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Tria Parallel Trial. TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease Trial. Available at: http://www.clinicaltrials.gov/ct/show/NCT00153101?order=1.
27.
Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272–279.
28.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002;62:956–962.
29.
Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260–269.
30.
Van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F: Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285–2292.
31.
Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006;70:2116–2123.
32.
Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126–3133.
33.
Palmer BF: Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007;27:287–293.
34.
Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C: Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005;16:3038–3045.
35.
Vogt L, Navis G, de Zeeuw D: Individual titration for maximal blockade of the renin angiotensin system in proteinuric patients: a feasible strategy? J Am Soc Nephrol 2005;16(suppl 1):S53–S57.
36.
Textor SC, Gephardt GN, Bravo EL, Tarazi RC, Fouad FM, Tubbs R, McMahon JT: Membranous glomerulopathy associated with captopril therapy. Am J Med 1983;74:705–712.
37.
Hoorntje SJ, Kallenberg CG, Weening JJ, Donker AJ, The TH, Hoedemaeker PJ: Immune-complex glomerulopathy in patients treated with captopril. Lancet 1980;1:1212–1215.
38.
Sturgill BC, Shearlock KT: Membranous glomerulopathy and nephritic syndrome after captopril therapy. JAMA 1983;250:2343–2345.
39.
Weinberg AJ, Zappe DH, Ashton M, Weinberg MS: Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004;24:340–345.
40.
Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS: Long-term safety of high-dose angiotensin receptor blockers therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl 2006;24:S95–S99.
41.
Nagai M, Horikoshi K, Izumi T, Seki S, Taniguchi M, Taniguchi I, Mochizuki S: Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 2004;18:353–362.
42.
Porteri E, Rodella L, Rissoni D, Rezzani R, Paiardi S, Sleiman I, De Ciuceis C, Boari GE, Castellano M, Bianchi R, Agabiti-Rosei E: Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Blood Press 2005;14:184–192.
43.
Fujihara CK, Velho M, Malheiros DM, Zatz R: An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005;67:1913–1924.
44.
Ma L-J, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB: Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966–976.
45.
Yu C, Gong R, Rifai A, Tolbert EM, Dworkin LD: Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol 2007;18:750–759.
46.
Rossing K, Schjoedt KJ, Jemsen BR, Boomsma F, Parving HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190–1198.
47.
Avapro® (irbesartan) Prescribing Information. New York, Bristol-Myers Squibb Sanofi-Synthelabo Partnership, October 2005.
48.
Atacand HCT Tablets® (candesartan) Prescribing Information. Wilmington, AstraZeneca, December 2005.
49.
Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921–1926.
50.
Diovan® (valsartan) Prescribing Information. East Hanover, Novartis Pharmaceutical Corp, November 2006.
51.
Aranda O, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, Lopez de Novales E: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005;46:1074–1079.
52.
Micardis® (telmisartan) Prescribing Information. Ridgefield, Boehringer Ingelheim Pharmaceuticals, Inc, May 2006.
53.
Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, Fogari E, Rinaldi A, Mugellini A: Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007;20:417–422.
54.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group: Prevention of transition form incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577–1578.
55.
Onuigbo MA, Onuigbo NT: Use of ultrahigh RAAS blockade: implications for exacerbation and renal function. Kidney Int 2006;69:194–195.
56.
Onuigbo MAC, Onuigbo NTC: Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 2005;11:CR462–CR469.
57.
Palmer BF: Renal dysfunction complicating treatment of hypertension. N Engl J Med 2002;347:1256–1261.
58.
Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585–592.
59.
High dose ACE inhibitor therapy versus combination ACE and ARB therapy. Clinical Trials.gov Identifier NCT00212901. Available at: http://clinicaltrials.gov/ct/show/NCT00212901. Accessed August 9, 2007.
60.
Higher dose of ramipril versus addition of telmisartan-ramipril in hypertension and diabetes. ClinicalTrials.gov Identifier NCT00208221. Available at: http://clinicaltrials.gov/ct/show/NCT00208221. Accessed August 8, 2007.
61.
High doses of candesartan cilexetil on the reduction of proteinuria. ClinicalTrials.gov Identifier NCT00242346. Available at: http://clinicaltrials.gov/ct/show/NCT00242346. Accessed August 9, 2007.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.